ICTI News
Interactive Clinical Technologies Incorporated (ICTI) is pleased to announce that it recently successfully completed implementation of a Storage Area Network (SAN).
Yardley, PA -- May 5, 2005 - Interactive Clinical Technologies Incorporated (ICTI) is pleased to announce that it recently successfully completed implementation of a Storage Area Network (SAN). The SAN is but one component of ICTI's High Availability Strategy.
Putting ICTI at the forefront of the IVRS and EDC markets, the SAN provides full state-of-the-art backup and disaster recovery for ICTI's clients. By maintaining a complete copy of all of ICTI's data in a geographically separate, secure location, the SAN ensures the integrity of clients' data in the case of a disaster. Data are written to the SAN in real time so that, unlike commonly used data backup procedures, there is no loss of data at ICTI in the event that ICTI's main location is damaged and/or unavailable.
The SAN has massive capacity, not being limited in scalability or performance in the way that local area networks are. It also increases the efficiency of system resources, leaving more system resources available for clients' applications.
Our clients' clinical systems auditors in particular appreciate the data protection provided by the high reliability and high performance of ICTI's fully validated SAN implementation.
Fritz Haas, ICTI's Vice President of Information Systems, reflected, "While the implementation of the SAN was a technology project, the impetus behind it was our commitment to complete customer satisfaction. That commitment means that we need to provide 100% data security and reliability. The SAN, along with our robust network environment, provides clients with that security."
About ICTI and Almac Sciences
ICTI is a division of Almac Sciences that specializes in interactive solutions to accelerate the clinical trials process and reduce the costs of clinical trials. Our solutions include Interactive Voice Response (iVR) for patient randomization, dosing and clinical supply management; phone-based patient diaries; iTrial EDC for clinical trials data; and forecasting for clinical trials supplies planning.
Almac Sciences and its affiliated companies (CSS (Chemical Synthesis Services), CTS (Clinical Trial Services), ICTI (Interactive Clinical Technologies Incorporated), PDMS (Pharmaceutical Development and Manufacturing Services) and ArraDx (Array Based Diagnostics)) provide a broad range of services across drug discovery, diagnostics, pharmaceutical research and development, manufacture of API, clinical trials and drug product manufacture. US operations are based in Pennsylvania, North Carolina and California. European operations are headquartered in Craigavon, Northern Ireland with additional operations in London and Edinburgh.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
